GlassScriptPhysician profile
Douglas Conaway
NPI 1316944499
$500,321.07
in general payments reported to CMS, 2019-2025
43 companies · $40K in 2025
The $40K reported for 2025 was more than what 95% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $225K · 2020: $61K · 2021: $40K · 2022: $45K · 2023: $61K · 2024: $29K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $93K · Travel and Lodging: $22K · Food and Beverage: $12K · Consulting Fee: $3,330 · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $92,901.00 |
| Travel and Lodging | $21,502.14 |
| Food and Beverage | $12,267.37 |
| Consulting Fee | $3,330.00 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $300,838.29 | 2019-2025 | Evenity, Prolia, Otezla |
| Janssen Scientific Affairs, LLC | $90,650.29 | 2019-2024 | Tremfya, Simponi Aria, Stelara |
| Janssen Biotech, INC. | $62,314.06 | 2019-2025 | Simponi Aria, Tremfya, Remicade |
| Pfizer INC. | $27,445.54 | 2019-2025 | |
| Abbvie INC. | $7,315.59 | 2019-2025 | Rinvoq, Skyrizi, Qulipta |
| Glaxosmithkline, LLC. | $4,014.52 | 2019-2024 | Benlysta |
| Ucb, INC. | $1,534.72 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Research & Development, LLC | $1,509.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $780.10 | 2019-2025 | |
| Genentech USA, INC. | $419.73 | 2019-2024 | Actemra |
| Janssen Pharmaceuticals, INC | $389.83 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $305.56 | 2019-2025 | Orencia |
| Horizon Therapeutics Plc | $275.68 | 2019-2023 | Krystexxa, Tepezza |
| Abbott Laboratories | $230.17 | 2020-2025 | Freestyle Libre 3 |
| Antares Pharma, INC. | $228.82 | 2019-2021 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $202.40 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Alexion Pharmaceuticals, INC. | $188.14 | 2023-2024 | Strensiq |
| Astrazeneca Pharmaceuticals LP | $182.44 | 2021-2022 | |
| Genzyme Corporation | $178.23 | 2022-2023 | |
| Celgene Corporation | $171.64 | 2019 | |
| Radius Health, INC. | $129.03 | 2019-2025 | Tymlos |
| Beta Bionics, INC. | $124.84 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Regeneron Healthcare Solutions, INC. | $101.96 | 2019 | |
| Mallinckrodt Hospital Products INC. | $95.97 | 2020-2022 | |
| Lilly USA, LLC | $93.99 | 2019-2024 | Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.27 | 2023-2025 | Jardiance, Ofev |
| Averitas Pharma INC. | $58.63 | 2023-2025 | Qutenza |
| Bayer Healthcare Pharmaceuticals INC. | $54.51 | 2024-2025 | |
| Astellas Pharma US INC | $50.96 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $46.58 | 2019-2021 | |
| Madrigal Pharmaceuticals | $44.28 | 2025 | Rezdiffra |
| Aurinia Pharma U.S., INC. | $36.99 | 2024 | Lupkynis |
| Boston Scientific Corporation | $36.30 | 2023-2024 | Watchman Flx, Watchman Access System |
| Dexcom, INC. | $29.01 | 2021-2023 | Dexcom G6 Transmitter |
| Insulet Corporation | $26.52 | 2022-2023 | Omnipod |
| Otsuka America Pharmaceutical, INC. | $22.39 | 2024 | Rexulti |
| Vital Connect, INC | $22.30 | 2023 | Vitalpatch Rtm |
| Daiichi Sankyo INC. | $16.71 | 2021 | |
| Merck Sharp & Dohme LLC | $14.82 | 2020 | |
| Eisai INC. | $14.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.72 | 2021 | |
| Amarin Pharma, INC. | $11.61 | 2021 | |
| Shire North American Group INC | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Conaway listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.